Abstract

Huntington disease (HD), a fatal neurodegenerative disorder, is caused by a lengthening of the polyglutamine tract in the huntingtin (Htt) protein. Despite considerable effort, thus far there is no cure or treatment available for the disorder. Using the approach of tandem affinity purification we recently discovered that prothymosin-α (ProTα), a small highly acidic protein, interacts with mutant Htt (mHtt). This was confirmed by co-immunoprecipitation and a glutathione S-transferase (GST) pull-down assay. Overexpression of ProTα remarkably reduced mHtt-induced cytotoxicity in both non-neuronal and neuronal cell models expressing N-terminal mHtt fragments, whereas knockdown of ProTα expression in the cells enhanced mHtt-caused cell death. Deletion of the central acidic domain of ProTα abolished not only its interaction with mHtt but also its protective effect on mHtt-caused cytotoxicity. Additionally, overexpression of ProTα inhibited caspase-3 activation but enhanced aggregation of mHtt. Furthermore, when added to cultured cells expressing mHtt, the purified recombinant ProTα protein not only entered the cells but it also significantly suppressed the mHtt-caused cytotoxicity. Taken together, these data suggest that ProTα might be a novel therapeutic target for treating HD and other polyglutamine expansion disorders.

Highlights

  • Abnormal huntingtin (Htt)-protein interactions are implicated in Huntington disease (HD)

  • Using the approach of tandem affinity purification we recently discovered that prothymosin-␣ (ProT␣), a small highly acidic protein, interacts with mutant Htt

  • In this report, using cell culture models of HD, we demonstrate that ProT␣ interacts with mutant Htt (mHtt) and reduces mHtt-caused cytotoxicity

Read more

Summary

Background

Abnormal huntingtin (Htt)-protein interactions are implicated in Huntington disease (HD). Using the approach of tandem affinity purification we recently discovered that prothymosin-␣ (ProT␣), a small highly acidic protein, interacts with mutant Htt (mHtt). This was confirmed by coimmunoprecipitation and a glutathione S-transferase (GST) pull-down assay. When added to cultured cells expressing mHtt, the purified recombinant ProT␣ protein entered the cells but it significantly suppressed the mHtt-caused cytotoxicity Taken together, these data suggest that ProT␣ might be a novel therapeutic target for treating HD and other polyglutamine expansion disorders. Huntington disease (HD), a fatal neurodegenerative disorder, is caused by an expansion of polyglutamine (polyQ) in the N-terminal region of the huntingtin (Htt) protein [1]. In this report, using cell culture models of HD, we demonstrate that ProT␣ interacts with mHtt and reduces mHtt-caused cytotoxicity

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call